Blog
RSS FeedPosted by Michael Wonder on 04 Dec 2018
NICE backs Cimzia for psoriasis, but rejects Ilumetri
4 December 2018 - Cost watchdog NICE has backed NHS funding for UCB’s Cimzia as a treatment for psoriasis, but ...
Posted by Michael Wonder on 30 Nov 2018
NICE U turn on Opdivo for skin cancer recurrence
30 November 2018 - NHS use of Bristol-Myers Squibb’s Opdivo to cut the risk of early stage skin cancer recurrence ...
Posted by Michael Wonder on 29 Nov 2018
Life extending treatment for patients with advanced liver cancer recommended by NICE
29 November 2018 - Approving regorafenib is a "welcome step forward" for those people who are eligible. ...
Posted by Michael Wonder on 28 Nov 2018
NICE publishes FAD for new indication for Xeljanz
28 November 2018 - NICE has published a final appraisal document for tofacitinib citrate for the treatment of patients with ...
Posted by Michael Wonder on 28 Nov 2018
First children set to receive Novartis’ Kymriah
27 November 2018 - The first children to receive Novartis’ Kymriah – a ‘game-changing’ CAR-T therapy for cancer - will ...
Posted by Michael Wonder on 27 Nov 2018
Pharma agrees to 2 percent cap on branded meds growth
25 November 2018 - The Association of the British Pharmaceutical Industry has agreed the terms of the 2019 Pharmaceutical Price ...
Posted by Michael Wonder on 27 Nov 2018
NHS saves record £300 million by switching to cheaper arthritis drug
26 November 2018 - The NHS is set to save a record £300 million after negotiating deals with five manufacturers ...
Posted by Michael Wonder on 26 Nov 2018
UK pharma industry reacts to outcome of European Council meeting
25 November 2018 - The European Council has endorsed the Agreement on the withdrawal of the UK from the EU and ...
Posted by Michael Wonder on 23 Nov 2018
Faster access to groundbreaking medicines as major milestones reached in deal with pharmaceutical industry
23 November 2018 - Cutting-edge and best value drugs will be fast-tracked through the approval process so patients can gain access ...
Posted by Michael Wonder on 23 Nov 2018
Multi-indication pricing: nice in theory but can it work in practice?
24 November 2018 - For medicines with different valued indications, multi-indication pricing implies charging different prices for different uses. ...
Posted by Michael Wonder on 23 Nov 2018
Lords ask Minister for clarity on access to medicine after Brexit
23 November 2018 - The House of Lords EU Home Affairs Sub-Committee has written to Matt Hancock MP, Secretary of ...
Posted by Michael Wonder on 22 Nov 2018
New life-extending lung cancer treatment approved by NICE
22 November 2018 - NICE today recommends in draft guidance that immunotherapy drug pembrolizumab (also known as Keytruda), used with ...
Posted by Michael Wonder on 19 Nov 2018
Pharma ignores the squabbling and prepares for a hard Brexit
19 November 2018 - Costs are irrecoverable in industry that has to plan for all possible scenarios. ...
Posted by Michael Wonder on 19 Nov 2018
Which databases should be used to identify studies for systematic reviews of economic evaluations?
16 November 2018 - This study investigated which databases and which combinations of databases should be used to identify economic evaluations ...
Posted by Michael Wonder on 19 Nov 2018
Innovative skin cancer drug available on Cancer Drugs Fund
19 November 2018 - Patients with a type of advanced skin cancer have a new treatment option as pembrolizumab, also known ...